Mesoporous silicon is a biocompatible, biodegradable material that is receiving increased attention for pharmaceutical applications due to its extensive specific surface. This feature enables to load a variety of drugs in mesoporous silicon devices by simple adsorption-based procedures. In this work, we have addressed the fabrication and characterization of two new mesoporous silicon devices prepared by electrochemistry and intended for protein delivery, namely: (i) mesoporous silicon microparticles and (ii) chitosan-coated mesoporous silicon microparticles. Both carriers were investigated for their capacity to load a therapeutic protein (insulin) and a model antigen (bovine serum albumin) by adsorption. Our results show that mesoporous silicon microparticles prepared by electrochemical methods present moderate affinity for insulin and high affinity for albumin. However, mesoporous silicon presents an extensive capacity to load both proteins, leading to systems were protein could represent the major mass fraction of the formulation. The possibility to form a chitosan coating on the microparticles surface was confirmed both qualitatively by atomic force microscopy and quantitatively by a colorimetric method.
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Introduction
Since the first works on the controlled delivery of biopharmaceutics, intensive research has focused on the design of new compositions capable of ensuring optimal encapsulation and release of these delicate and complex drugs. The use of composite nanostructured materials in pharmaceutical technology is a powerful approach that opens new possibilities for the development of highly functional drug delivery devices. Better known in microelectronics, nanostructured semiconductors have been recently recognized to bear great promise for biomedical purposes such as tissue engineering [1] , medical diagnosis [2] , and drug delivery [3, 4] . One of the most interesting features of porous silicon is its longterm stability at low pH (<6.0) [5] and the high hydrophobic nature of its native surface that can be extremely advantageous for the adsorption and delivery of small hydrophobic molecules such as doxorubicin [6] , dexamethasone [7] or porphyrins [8] . Although the biocompatibility status of mesoporous silicon is still under investigation, it is known that the bulk material has negligible cytotoxicity [9] . Similar positive results have been observed for mesoporous silicon microparticles particles with sizes above 10 μm [10] . Mesoporous silicon is also biodegradable, and the kinetics of this process can be tailored both by modulating particles and size and by modifying the chemistry of its surface [11] . Overall, mesoporous silicon is attracting interest in the pharmaceutical field and several recent reviews have addressed its potential for controlled release devices [12, 13] .
The most distinctive property of mesoporous silicon is its extremely large specific surface area arising from it complex nanostructure. This specific surface area is commonly greater that 300 m 2 /g, and hence, it allows loading many kinds of drugs by simple adsorption. Adsorption-based loading procedures can be optimal for protein formulation, considering that the delicate tertiary structure of these molecules should be preserved to maintain their bioactivity. Mesoporous silicon structure and chemistry (i.e. pore diameter, surface chemical terminations) can be easily tailored leading to controlled dissolution rates under physiological conditions. By careful fine-tuning the porous silicon carrier properties it is possible 3 to attain zero order drug release kinetics and develop novel pharmaceutical devices such as insulin pumps [14, 15] and gastrointestinal patches for oral insulin delivery [16, 17] . Some recent studies have studied protein loading into porous silicon layers [18] [19] [20] [21] , and there is a general consensus that this is a complex process that can be influenced by the morphology of the silicon device, its nanostructure, and the device surface chemistry [22] . However a systematic approach would improve our understanding of the physicochemical processes involved in protein-porous silicon interaction, and ultimately, it would lead to optimized formulations for protein delivery.
For mesoporous silicon systems intended for transmucosal drug delivery, a suitable particle size might be 10-30 μm, since they combine low toxicity with high available surface area for potential interaction with biological mucosae [10] . In this work, we have studied thermoxidized mesoporous silicon prepared by an electrochemical method in the form of microparticles (MS-MPs) as potential drug delivery devices for a therapeutic protein (insulin) and a model antigen (bovine serum albumin, BSA).
These two proteins present very different physicochemical properties, making them suitable models to perform comprehensive studies characterizing protein adsorption on MS-MPs. At a subsequent stage, MS-MPs were modified through the deposition of a chitosan (CS) coating, thus forming a multifunctional silicon/polymer composite with potential for advanced biomedical applications, a concept that has been recently explored in some recent works [23, 24] . The rational behind the selection of CS as the coating polymer was: (i) its know capacity to adsorb to polyactionic surfaces, (ii) its established pharmaceutical record, (iii) and its mucoadhesivess and permeation enhancing properties [25] [26] [27] [28] . The global concept was to generate a drug delivery system that would combine silicon drug loading properties with the unique characteristics of CS-coated systems for transmucoal drug delivery.
The final composite system should also provide adequate release kinetics and be presented in an easily administered form.
In the supplementary material ( Figure S1 ) we illustrate the step-by-step procedure followed for the preparation of the different MS-MPs formulations.
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Materials.
The following chemicals were obtained from commercial sources and used as received.
Silicon from Si Materials from Germany, boron doped with a resistivity of 0.01-0.02 Ohm . cm (p+);
wafer diameter was 100.0± 0.5 mm and thickness of 525 ± 25 mm (isoelectric point (pI)= ~ 2 -3.5 purified from a batch of squid pen CS (from Mathani, France). Their Mw, expressed as degree of polymerization (DP), low (LDP) or high (HDP), and the degree of acetylation (DA, %) were characterized by HPLC-MALLS-DRI and 1 H NMR spectroscopy, respectively, as described elsewhere [29] . These four CS samples were: (i) HDP (266000 g/mol)-DA 56, pKa=6.80; (ii) HDP (124000 g/mol)
-DA 1 pKa=6.46, (iii) LDP (13200 g/mol) -DA 1-pKa=6.46 and (iv) LDP (11420g/mol)-DA 51, pKa=6.74. CS was dissolved in 5% stoichiometric excess of acetic acid in aqueous solution. All other reagents were of analytical grade. Milli-Q water was used throughout the study.
Preparation of mesoporous silicon microparticles (MS-MPs).
Porous silicon layers were prepared through an electrochemical treatment of the p+ silicon wafer (with 4 inches of diameter) in fluoric acid (48%): ethanol (96%) 1:2 electrolyte under 50 mA/cm 2 of current density. During the electrochemical treatments, the front side of the wafer was exposed to the electrolyte. After 1 hour of anodizing, the 5 thickness of the porous layer was approximately 300 µm. The silicon wafer was then washed throughout with distilled water and the porous fraction scratched from the remnant silicon wafer. To stabilize this mesoporous silicon layer a thermal oxidation process was performed under a synthetic air atmosphere at 450ºC for one hour (Ivoclar-Vivadent Technical Owen, Programat P200 equipped with a vacuum pump VP3 and gas inlet). To reduce the particle size to the micrometer scale, the mesoporous silicon layer was milled and sieved in cascade. The fraction between 30 and 100 μm was selected for further studies.
Henceforth this fraction is referred to as mesoporous silicon microparticles (MS-MPs). equipped with a monochromatic Alα(1486.6eV) X-ray source).
To determine the particle size distribution of MS-MPs, samples were analysed by an optical microscope (Olympus BX60) equipped with a video camera and linked to a computer with an image analyzing software (VGA 24 Analyser Software). Pictures were first digitalized with a Matrox Comet video card (Matrox Electronic Systems). Particle size distribution was found to be log-normal (r 2 >0.99) and average particle size and standard deviation was calculated after fitting particle distribution to this model. The morphology of unloaded or protein-loaded MS-MPs was visualized by high resolution Scanning Electron Microscopy (SEM, Hitachi S4500). Additionally, the BET surface area of the MS-6
MPs sample was determined by N2 adsorption-desorption isotherms (Micrometrics ASAP 2020 V3.04H, Micromeritics France S.A., France). by measuring the concentration of non-attached CS after isolation of the free CS solution from the MSMPs (12800 x g during 10 min at 37ºC). CS concentration was determined through a colorimetric test based in the reaction of CS with Cibacron brilliant red 3B-A [30] . The influence of CS physicochemical parameters on its capacity to associate to MS-MPs was studied.
Protein-loading of MS-
Atomic Force Microscopy (AFM) was used to observe the surface of the CS coated samples (unloaded and protein-loaded). AFM was performed in air using the NanoScope III by Digital Instruments operating in tapping mode. Nanoscope 4.43r8 software was used for data analysis.
In vitro protein release study. Insulin release was studied in vitro by incubating aliquots of insulin- 
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Result and Discussion
In this work we have studied mesoporous silicon microparticles (MS-MPs) prepared by a new electrochemical method as drug delivery devices for a therapeutic protein (insulin) and a model antigen (BSA). Firstly, we studied the physico-chemical properties of unloaded MS-MPs, including chemical composition, nanostructure and porosity. In a second stage, we systematically characterized the capacity of these compositions to load these proteins, providing further mechanistic insight on proteinmesoporous silicon interaction. Finally, unloaded and protein loaded MS-MPs were modified with 8 chitosan (CS) coating. The capacity of uncoated and CS-coated MS-MPs to release insulin was studied.
The overall experimental approach is depicted in the supplementary material ( Figure S1 ).
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Preparation and characterization of porous silicon carriers. A porous silicon layer was prepared electrochemically and surface-modified afterwards by thermal oxidation as described in the methods section. Silicon oxidation is a superficial chemical treatment performed (i) to reduce the hydrophobicity of the starting material, (ii) to increase its chemical stability in aqueous solvents [31] [32] and (iii) to control silicon-protein interactions [33] . Chemical analysis of the mesoporous silicon wafer used for microparticles preparation is shown in Figure 1 . An FTIR spectrum of the Si-Hx vibration region of the native silicon layer before and after the oxidative treatment is shown in Figure 1A . MS-MPs were prepared by dry milling of the oxidized mesoporous silicon layer, and therefore they represent an industry-friendly top-down alternative to the more classical bottom-up supramolecular 9 synthesis strategies. SEM images confirmed the formation of particles with a log-normal particle sized distribution. Average particle size was 33.1 μm, and standard deviation 27.3 μm (Figure 2A ). Figure 2B illustrates the resulting particle size expressed as a volume fraction distribution. The presence of a minor fraction (6-8% of the particles in volume distribution) with sizes larger than 80 μm can be associated with agglomeration or irregular shape. This fraction of aggregated particles is relatively small is we take it from a particle number percentage rather than by volume distribution. The inner structure of MS-MPs was characterized by SEM imaging (2C, 2D) and N2 adsortion/desortion isotherms (2E, isotherms; 2F, surface area/pore volume). MS-MPs are characterized by an average pore diameter of 22.5 nm (N2 adsorption, BJH calculation scheme) and a BET Surface Area of 341.5219 m²/g. It is known that porous silicon prepared with p + -type doped wafer consists on long tubular cavities running perpendicular to the surface, another distinctive feature of MS-MPs as compared to silicon particles prepared by supramolecular chemistry [34] . Figure 2C and 2D substantiate the order of magnitude of this pore size and this regular pore arrangement. The porosity of the material was 83 ±4 %, as determined gravimetrically.
Protein loading. Considering the outstanding specific surface of MS-MPs (~340 m 2 /g), we
hypothesized that these nanostructured systems could be highly suitable for loading biopharmaceuticals by adsorption. Adsorption of biopharmaceuticals from aqueous solutions is an ideal method for drug loading since it does not require high mechanical energy, use of organic solvents or high temperatures, factors that might lead to the denaturation or chemical degradation of protein drugs. In this work, we have studied the capacity of MS-MPs to load two different proteins by adsorption, namely insulin and BSA. In Figure 3A the adsorption isotherms of insulin onto MS-MPs are presented at two pH values. The corresponding BSA adsorption isotherms are shown in Figure 3B . In all experiments, protein concentrations in the protein solution were always below their solubility limit, which was only limiting for insulin at pH 7.4 (4-4.5 mg/ml).
Insulin adsorption isotherms were linear at both pH values, indicating that no saturation point in the adsorption process is achieved with the highest equilibrium concentration tested. Acidic media (pH 3.8) favored insulin adsorption as the slope between amount of insulin adsorbed and equilibrium concentration almost doubled as compared to that at pH 7.4. In the case of the BSA isotherms at pH 3. Figure   4A ). This value was approximately maintained through all the studied concentration range. At low insulin concentrations, some differences on protein adsorption were observed at pH values of 3.8 and 7.4. The AE of insulin at pH 3.8 was always close to the maximum value. At pH 7.4, insulin AE increased linearly between 0 and 0.6 mg/mL of insulin concentration and then reached a stable maximum. In both cases, the insulin LC in MS-MPs increased in a linear fashion over the studied concentration range ( Figure 4C ). Under the current experimental setup we reached LC values around 50%, i.e. an equivalent mass of silicon and proteins loaded in the formulation.
The association of BSA follows a different behaviour than insulin at low pH. In this case, the AE of BSA to MS-MPs is very high at low protein concentrations and is slightly reduced as the amount of BSA in solution increases. This profile suggests a high affinity adsorption process that is partly saturated by the increasing BSA concentration. A possible explanation would be initial binding mediated by electrostatic forces, based on the opposite charge of oxidized silicon and BSA at pH 3.8. As the BSA added increases, most protein would be just adsorbed by hydrophobic interactions. BSA association at 11 pH 7.4, on the other hand, shows a very similar profile to that observed with insulin: a progressive AE increase at low concentrations that peaks between 1mg/mL and 3 mg/mL (~80% AE), but is reduced for very high BSA concentrations (25 mg/mL). Considering the amounts of protein adsorbed it is very likely that a large fraction of the proteins will be loaded in this inner structure. That is also a logical conclusion sinece the radius of gyration of both proteins (1.5 and 3 nm approximately for insulin and BSA, respectively) is well below the pore size of the prepared MS-MPs (34 nm).
MS-MPs
In summary, the experimental evidence presented above confirms the excellent properties of MS-MPs as devices capable of loading therapeutic proteins. Furthermore, these experiments highlight the complexity of the adsorption process, which depends on the nature of the protein to be loaded, on the concentration of the protein solution used for adsorption, and on physicochemical parameters such as the pH. Future work will focus on studying the possibility to control protein adsorption parameters through surface modification or modulation of the carrier porosity. 12
Chitosan coating. Chitosan (CS) is a biodegradable, biocompatible polysaccharide with interesting features for drug delivery applications [36] . Among such features, it is worth mentioning that CS can act as a pH-sensitive controlled release polymer, that it can form polymer coatings with mucoadhesive characteristics, and that it is also a mucosal penetration enhancer. Based on these properties, we aimed at modifying the surface of MS-MPs by coating it with this polymer. To this end, modification was performed firstly in unloaded carriers and subsequently in protein-loaded ones.
Unloaded MS-MPs were used in preliminary experiments aimed to establishing the optimal pH for the CS-coating process. These studies indicated that CS does not attach to MS-MPs at strongly acidic pH values (pH 1-2), and is insoluble at neutral or basic pH. Significant CS attachment to the MS-MPs material was found in acetate buffer of pH 3.8, a buffer where CS is invariably positively charged (i.e. pKa~ 6.5 -6.8). This could account for its adsorption onto the anionic porous silicon surface. We also observed that CS-coating in this acidic medium was time-dependent, and allowed us to form mixed silicon/CS systems where the coating polymer accounted for nearly 30% of the final formulation weight over a period of one week. However, to reduce possible MS-MPs degradation in the aqueous solvent, and potential protein release in further studies dealing with loaded particles, the CS-coating process was limited to 1 h of co-incubation. According to a previous study [13] , it is estimated that only 10% or less of the MS-MPs weight could be lost under the selected experimental conditions.
Once established the optimal coating method, we investigated the effect of CS chemical properties (molecular weight, degree of acetylation) and CS concentration in the efficiency of CS incorporation into the final system. CS-coating efficiency was measured by quantifying CS through a colorimetric method. Table 1 summarizes the CS coating efficiencies achieved. This parameter measures the percentage of the original CS mass that is incorporated into the formulation during the coating procedure. In general, all CS samples exhibited low affinities for the MS-MPs, with CS-coating efficiencies below 4%. As we have mentioned, efficient CS absorption required rather long incubation times, suggesting that longer times might be beneficial to induce some cooperative binding of CS. 13
Additionally, CS has large gyration radius (37-96 nm; F.M. Goycoolea, unpublished work) as compared to the average pore size of MS-MPs (~35 nm). Hence, CS penetration to the inner structure would be sterically hindered, resulting on specific CS deposition on the external shell of the MS-MPs. The external surface of the MS-MPs is several orders of magnitude lower than the total surface of the system, and this might be an important reason for the moderate fractions of CS bound. This hindered penetration of CS, however, could be considered advantageous since it allows depositing a CS coating layer without interfering in the inner carrier structure.
From our experiments with different CS samples, we can draw the following general rules regarding their capacity to coat MS-MPs. Firstly, CS with low degrees of acetylation are more efficient for coating than samples of CS with high degree of acetylation (Table 1) the surface of dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) bilayers, it has been observed that the increase of CS Mw leads to a dramatic reduction in the cooperative unit and hence an increase in effective contact area between individual CS and the lipid bilayer [37] . This reduction in the cooperative effective length against Mw implies that CS swirls across the surface bilayer, thus forming 'trains' [38] . 14 A similar mechanism may operate for the interaction between CS and MS-MP surface. Based on these results we decided to use HDP-DA1 CS and fix its concentration in the coating solutions to 0.7 mg/mL, the concentration that rendered the most efficient process.
On protein-loaded MS-MPs we initially aimed at confirming that the coating process would not induce the release of significant amounts of the loaded proteins. Our experiments confirmed that BSA release during CS-coating is negligible, while it amounts to less than 20% in the case of insulin-loaded materials. Altogether, these results indicate the success of our coating optimized protocol. CS mass percentages around 2-4% in the formulation might seem insufficient for preparing useful coatings. However, it should be considered that MS-MPs are 33 μm in size, and thus, this system presents a moderate specific surface for molecules with restricted access to the mesopores. For such systems, relatively small amounts of coating polymers are necessary for surface modification.
In Vitro Release. In vitro tests were conducted to study insulin release from MS-MPs at two different pH values (7.4 and 5.5), and under sink conditions. Experiments were performed both for uncoated and CS-coated MS-MPs and the results are presented in Figure 6 . At pH 5.5 both uncoated and CS-coated 15
MS-MPs showed similar (probably due to the chitosan swell) biphasic release profiles: an initial burst of 30-35%, a slow release of another 10% of the cargo up to 45 minutes, and then a fast release of the protein (30-40% of the cargo) in the next 15 minutes. At pH 7.4, both uncoated and CS-coated formulations showed a more progressive release profile. In uncoated MS-MPs, insulin burst release was restricted to 20% of the payload, and 60% of the loaded peptide was released by the 45 min time point.
For CS-coated MS-MPs, a slower release profile was detected: burst release was also restricted to 20% of the total insulin, while further 40% was released by the 45 min time point. In this particular case, 90% insulin release was reached approximately after 90 min.
Both MS-MPs show fast, but controlled release of insulin, as illustrated by the low burst effect and the capacity of the formulation to maintain insulin release for more than 1 h. This contrasts with more uncontrolled profiles typical from some other CS-based delivery devices such as CS nanoparticles [38] .
Considering that MS-MPs are not expected to degrade in such short time spans, and the progressive release kinetics observed for CS-coated MS-MPs at pH 7.4, we believe that insulin release from MSMPs must be diffusion-controlled. This diffusion-controlled kinetic would be related both to insulin transport through the nanometric pores, and to insulin transport through the CS-coating. Interestingly, 
